1510sek
7,1 %
Date:2025-05-14Time:16:59:20Latest report:Q1-2025List:First NorthTicker:GUARD
Market Cap:305 msekEnterprise Value:288 msekNet Sales:- msekEarnings:-115,8 msekEmployees:0ISIN:SE0021181559

Ratios

10-year key figure history for Guard Therapeutics turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Guard Therapeutics with index and moving average MA50 and MA200.

Stockprice:15,10
MA50:14,79
MA200:22,17
Price/MA200:-31,9 %
RSI (14):60,6
Price/MA50:2,1 %

Description

Guard Therapeutics is a developer of pharmaceuticals in the field of oxidative stress. The company focuses primarily on the research, development, and commercialization of pharmaceuticals that are intended to prevent the occurrence and complications of acute kidney damage. In preclinical studies, pharmaceuticals have been shown to protect exposed tissue and support regenerative processes. Treatment of acute kidney injuries in conjunction with heart surgery is a priority in clinical development.

Biotechnology